In this case, CDH2 and MCP-1 mRNAs from blood EVs not only have diagnostic potential for early-stage DN, but also could be promising target points to understand underlying mechanisms of DN progression and develop an alternative approach for the prevention, prognosis, and treatment of DN. The gene discussed is CCL2; the disease is liver dysplastic nodule.